Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/21/2024 | $9.00 → $4.00 | Buy → Neutral | UBS |
| 8/15/2023 | $40.00 → $4.00 | Buy → Neutral | Mizuho |
| 7/17/2023 | Buy → Neutral | Guggenheim | |
| 3/10/2023 | $20.00 → $22.00 | Buy → Hold | Jefferies |
| 12/1/2022 | $16.00 | Sell → Neutral | Goldman |
| 7/7/2022 | $19.00 | Buy | Mizuho |
| 4/6/2022 | $80.00 | Buy | BofA Securities |
| 2/16/2022 | $88.00 → $25.00 | Buy | UBS |
UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously
Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously
Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral